Maria Luisa Pineda, PhD, CEO and co-founder of Envisagenics was recently featured in WuXi AppTec’s interview series on the topic; Delivering on the Promise of New Modalities. Portfolio company Envisagenics focuses on diseases driven by splicing deregulation. They are applying their AI-driven platform SpliceCore to identify these irregularities and to develop novel RNA splicing therapeutics.